Time to end treatment restrictions for people with hepatitis C who inject drugs

The Lancet Gastroenterology & Hepatology

First published: 05 January 2018

DOI: http://dx.doi.org/10.1016/S2468-1253(18)30001-3

Elana S Rosenthal, Sarah Kattakuzhy, Shyam Kottilil

Objective: Hepatitis C virus (HCV) is a major cause of liver-related morbidity and mortality worldwide. Ongoing transmission is mostly driven by people who inject drugs (PWID), among whom global HCV antibody prevalence is 52·3%. Although direct-acting antiviral therapy has made this infection curable in most patients, PWID remain largely untreated.

 SEGUIR LEYENDO